RecruitingPhase 2

Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

United States180 participantsStarted 2025-08-06

Plain-language summary

Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP.

Age range55 Years – 84 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. The subject's LAR must provide written informed consent.
✓. The subject must provide written (if capable) informed assent per local regulations.

Change from Baseline in SAPS-LBDP total score at Week 6

Timeframe: 6 weeks

NCT IDNCT07029581

SponsorACADIA Pharmaceuticals Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2028-02

Kristin Kidd